Page last updated: 2024-10-24

carvedilol and Pulmonary Hypertension

carvedilol has been researched along with Pulmonary Hypertension in 11 studies

Research Excerpts

ExcerptRelevanceReference
" • Carvedilol reduced biventricular TGFβ1-CTGF signaling, fibrosis, and apoptosis."7.81Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. ( Breitling, S; Friedberg, MK; Honjo, O; Kato, H; Kuebler, WM; Okumura, K; Sun, M, 2015)
"We report a case of macroscopic T-wave alternans occurring 30 min before the onset of amiodarone-induced torsade de pointes, illustrating a means to monitor for proarrhythmia."7.78In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights. ( Aoyama, T; Hattori, A; Kanamori, H; Kawaguchi, T; Kawasaki, M; Kubota, T; Minatoguchi, S; Nishigaki, K; Takasugi, M; Takasugi, N; Takemura, G; Ushikoshi, H; Verrier, RL, 2012)
"To study the condition of the sympathico-adrenal system (SAS), synthesis of cAMP dependent on beta2-adrenoreceptors and parameters of free radical oxidation in patients with primary pulmonary hypertension (PPH); to examine efficacy of non-selective beta- and alpha1-adrenoblocker carvedilol in PPH patients."7.73[Primary pulmonary hypertension: activation of sympathico-adrenal system and free radical oxidation. Positive effects of carvedilol therapy]. ( Aref'eva, TI; Ataullakhanova, DM; Chazova, IE; Irodova, NL; Konovalova, GG; Krasnikova, TL; Lankin, VZ; Lazutkina, VK; Masenko, VP; Orlova, IaA; Sokolov, SF, 2005)
"To evaluate carvedilol effect on clinical state, norepinephrine (NE) and epinephrine (E) plasma concentration and lymphocyte beta 2-adrenoreceptor dependent cAMP synthesis in patients with primary pulmonary hypertension (PPH)."7.71[Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrener ( Chazova, IE; Irodova, NL; Kochetov, AG; Krasnikova, TL; Masenko, VP, 2002)
"Genes encoding proteins in the cardiac hypertrophy and protein ubiquitination pathways were downregulated in the RV by carvedilol, while genes encoding proteins in the mitochondrial dysfunction pathway were upregulated by carvedilol."5.39Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. ( Bogaard, HJ; Drake, JI; Dumur, CI; Fawcett, P; Gomez-Arroyo, J; Kraskauskas, D; Natarajan, R; Voelkel, NF, 2013)
" • Carvedilol reduced biventricular TGFβ1-CTGF signaling, fibrosis, and apoptosis."3.81Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. ( Breitling, S; Friedberg, MK; Honjo, O; Kato, H; Kuebler, WM; Okumura, K; Sun, M, 2015)
"We report a case of macroscopic T-wave alternans occurring 30 min before the onset of amiodarone-induced torsade de pointes, illustrating a means to monitor for proarrhythmia."3.78In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights. ( Aoyama, T; Hattori, A; Kanamori, H; Kawaguchi, T; Kawasaki, M; Kubota, T; Minatoguchi, S; Nishigaki, K; Takasugi, M; Takasugi, N; Takemura, G; Ushikoshi, H; Verrier, RL, 2012)
"To assess the effect of the adrenergic receptor blocker carvedilol on the pulmonary circulation and right heart in experimental pulmonary hypertension in rats."3.76Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. ( Abbate, A; Bogaard, HJ; Chang, PJ; Chau, VQ; Hoke, NN; Kasper, M; Kraskauskas, D; Mizuno, S; Natarajan, R; Salloum, FN; Voelkel, NF, 2010)
"To study the condition of the sympathico-adrenal system (SAS), synthesis of cAMP dependent on beta2-adrenoreceptors and parameters of free radical oxidation in patients with primary pulmonary hypertension (PPH); to examine efficacy of non-selective beta- and alpha1-adrenoblocker carvedilol in PPH patients."3.73[Primary pulmonary hypertension: activation of sympathico-adrenal system and free radical oxidation. Positive effects of carvedilol therapy]. ( Aref'eva, TI; Ataullakhanova, DM; Chazova, IE; Irodova, NL; Konovalova, GG; Krasnikova, TL; Lankin, VZ; Lazutkina, VK; Masenko, VP; Orlova, IaA; Sokolov, SF, 2005)
"To evaluate carvedilol effect on clinical state, norepinephrine (NE) and epinephrine (E) plasma concentration and lymphocyte beta 2-adrenoreceptor dependent cAMP synthesis in patients with primary pulmonary hypertension (PPH)."3.71[Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrener ( Chazova, IE; Irodova, NL; Kochetov, AG; Krasnikova, TL; Masenko, VP, 2002)
"Genes encoding proteins in the cardiac hypertrophy and protein ubiquitination pathways were downregulated in the RV by carvedilol, while genes encoding proteins in the mitochondrial dysfunction pathway were upregulated by carvedilol."1.39Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. ( Bogaard, HJ; Drake, JI; Dumur, CI; Fawcett, P; Gomez-Arroyo, J; Kraskauskas, D; Natarajan, R; Voelkel, NF, 2013)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (45.45)29.6817
2010's6 (54.55)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gomez, O1
Okumura, K2
Honjo, O2
Sun, M2
Ishii, R1
Bijnens, B1
Friedberg, MK2
Drake, JI1
Gomez-Arroyo, J1
Dumur, CI1
Kraskauskas, D2
Natarajan, R2
Bogaard, HJ3
Fawcett, P1
Voelkel, NF3
Grinnan, D1
Grizzard, J1
Van Tassell, B1
Abbate, A2
DeWilde, C1
Priday, A1
Kato, H1
Breitling, S1
Kuebler, WM1
Mizuno, S1
Chang, PJ1
Chau, VQ1
Hoke, NN1
Kasper, M1
Salloum, FN1
Kawaguchi, T1
Takasugi, N1
Kubota, T1
Takasugi, M1
Kanamori, H1
Ushikoshi, H1
Hattori, A1
Aoyama, T1
Kawasaki, M1
Nishigaki, K1
Takemura, G1
Minatoguchi, S1
Verrier, RL1
Irodova, NL2
Krasnikova, TL2
Masenko, VP2
Kochetov, AG1
Chazova, IE2
Aref'eva, TI1
Lazutkina, VK1
Orlova, IaA1
Sokolov, SF1
Ataullakhanova, DM1
Konovalova, GG1
Lankin, VZ1
Fujio, H1
Nakamura, K1
Matsubara, H1
Kusano, KF1
Miyaji, K1
Nagase, S1
Ikeda, T1
Ogawa, A1
Ohta-Ogo, K1
Miura, D1
Miura, A1
Miyazaki, M1
Date, H1
Ohe, T1
Valencia Ortega, ME1
Ortega Millán, G1
Guinea Esquerdo, J1
Laguna Cuesta, F1
Moreno Celda, V1
Gónzalez Lahoz, J1
Eulalia Valencia, M1
Guinea, J1
Moreno, V1
González-Lahoz, J1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension[NCT00964678]Phase 1/Phase 210 participants (Actual)Interventional2010-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Absolute Change in Right Ventricular Ejection Fraction

Change in right ventricular ejection fraction is measured by cardiac magnetic resonance imaging, using the method of disks with the reading radiologist being blinded to before and after images. Cardiac magnetic resonance imaging was done at baseline and 6 months only (NCT00964678)
Timeframe: baseline, 6 months

Intervention% RVEF (Mean)
Carvedilol10.4

Change in 6 Minute Walk Distance

(NCT00964678)
Timeframe: baseline and 6 months

Interventionfeet (Number)
Participant 1Participant 2Participant 3Participant 5Participant 6
Carvedilol4516035596

Change in Right Ventricular End Systolic Volume

right ventricular end systolic volume determined by MRI (NCT00964678)
Timeframe: baseline and 6 months

InterventionmL (Number)
Participant 1Participant 2Participant 3Participant 4Participant 5Participant 6
Carvedilol31456112725

Change in Tricuspid Annular Plane Systolic Excursion

Higher values indicate a better outcome. (NCT00964678)
Timeframe: baseline and 6 months

Interventioncentimeters (Number)
Participant 1Participant 2Participant 4Participant 5Participant 6
Carvedilol0.4-0.08-0.120.450.08

Trials

1 trial available for carvedilol and Pulmonary Hypertension

ArticleYear
Treatment of group I pulmonary arterial hypertension with carvedilol is safe.
    American journal of respiratory and critical care medicine, 2014, Jun-15, Volume: 189, Issue:12

    Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Drug Administration Schedule; Familial Pr

2014

Other Studies

10 other studies available for carvedilol and Pulmonary Hypertension

ArticleYear
Heart rate reduction improves biventricular function and interactions in experimental pulmonary hypertension.
    American journal of physiology. Heart and circulatory physiology, 2018, 03-01, Volume: 314, Issue:3

    Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Carvedilol; Disease Models, Animal; Dr

2018
Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension.
    Physiological genomics, 2013, Jun-17, Volume: 45, Issue:12

    Topics: Animals; Carbazoles; Cardiomegaly; Carvedilol; Cluster Analysis; Gene Expression Profiling; Gene Exp

2013
Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension.
    Journal of molecular medicine (Berlin, Germany), 2015, Volume: 93, Issue:6

    Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Connective Tissue Growth Factor; Fibrosis;

2015
Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.
    American journal of respiratory and critical care medicine, 2010, Sep-01, Volume: 182, Issue:5

    Topics: Adrenergic Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Hypertension, Pulmo

2010
In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights.
    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2012, Volume: 14, Issue:9

    Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle-Branch Block; Carbazoles; Carv

2012
[Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrener
    Terapevticheskii arkhiv, 2002, Volume: 74, Issue:8

    Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiac Output, Low; Carvedilol; Catecho

2002
[Primary pulmonary hypertension: activation of sympathico-adrenal system and free radical oxidation. Positive effects of carvedilol therapy].
    Terapevticheskii arkhiv, 2005, Volume: 77, Issue:4

    Topics: Adrenergic Agents; Adult; Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Catalase; Female; F

2005
Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension.
    Journal of cardiovascular pharmacology, 2006, Volume: 47, Issue:2

    Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Cell Division; Cell P

2006
[Pulmonary hypertension in patients with human immunodeficiency virus infection. Study of 14 cases].
    Medicina clinica, 2000, Jul-01, Volume: 115, Issue:5

    Topics: Adult; Antihypertensive Agents; Carbazoles; Carvedilol; Echocardiography, Doppler; Female; Follow-Up

2000
[Severe pulmonary hypertensión treated with low dose carvedilol in a patient infected with the human immunodeficiency virus].
    Enfermedades infecciosas y microbiologia clinica, 2001, Volume: 19, Issue:8

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Female; HIV Infections

2001